New: Introducing the Finviz Crypto Map

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Latest News

Jul-25	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect ALKS Zacks
Jul-25	Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results? VRNA Zacks
Jul-24	Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors EXEL Business Wire
Jul-24	Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 KNSA GlobeNewswire
Jul-24	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect ALKS Zacks
Jul-24	Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? IMCR Zacks
Jul-23	Exelixis Gains Analyst Confidence as Cancer Studies Advances EXEL Insider Monkey
Jul-23	Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? ALKS EXEL Zacks
Jul-23	GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth ALKS Zacks
Jul-23	Here's Why Exelixis (EXEL) is a Strong Growth Stock EXEL Zacks
Jul-23	What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings EXEL Zacks
Jul-22	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? ALKS EXEL Zacks
Jul-22	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study ALKS Zacks
Jul-22	SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny VRNA Zacks
Jul-21	Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia ALKS Insider Monkey

Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.